AUTOMOTIVE PARTS ANTITRUST LITIGATION definition

AUTOMOTIVE PARTS ANTITRUST LITIGATION. 2:12-md-02311 Xxxxxxxxx Xxxxxxxx X. Battani Case No. 2:13-cv-01101-MOB-MKM Case No. 2:14-cv-10674-MOB-MKM Case No. 2:18-cv-11569-MOB-MKM IN RE STARTERS THIS DOCUMENT RELATES TO: DIRECT PURCHASER ACTIONS This Settlement Agreement (“Agreement”) (as more particularly defined in Paragraph 1 below) is made and entered as of April 21, 2020 (“Effective Date”) by and between Xxxxxx Xxxxx XxxX and Xxxxxx Xxxxx LLC (together, “Bosch” or the “Bosch Defendants”), and Direct Purchaser Plaintiff (as defined in Paragraph 3), both individually and on behalf of a class of direct purchasers of Starters (“Settlement Class”), as more particularly defined in Paragraph 10 below.
Sample 1
AUTOMOTIVE PARTS ANTITRUST LITIGATION. 2:12-md-02311 Xxxxxxxxx Xxxxxxxx X. Battani Case No. 2:16-cv-03703-MOB-MKM IN RE EXHAUST SYSTEMS THIS DOCUMENT RELATES TO: END-PAYOR ACTION This Settlement Agreement (“Agreement”) is made and entered into this 11th day of September 2017 (“Execution Date”) by and between Eberspächer Exhaust Technology GmbH & Co. KG and Eberspächer North America Inc. (together, “Eberspächer”), and End- Payor Plaintiff Class Representatives (“End-Payor Plaintiffs”), both individually and on behalf of a class of indirect purchasers of Exhaust Systems (“Settlement Class”), as more particularly defined in Paragraph 12 below.
Sample 1
AUTOMOTIVE PARTS ANTITRUST LITIGATION. Master File No. 2:12-md-02311 Judge Xxxxxxxx X. Xxxxxxx Magistrate Judge Xxxx X. Xxxxxxx Case No. 2:12-cv-00103 IN RE WIRE HARNESS SYSTEMS THIS DOCUMENT RELATES TO: END-PAYOR ACTION This Settlement Agreement (“Agreement”) is made and entered into this 2nd day of August, 2016 (“Execution Date”) by and between Tokai Rika Co., Ltd. and TRAM, Inc. d/b/a Tokai Rika U.S.A. Inc. (collectively, “TOKAI RIKA”) and End-Payor Plaintiff Class Representatives (defined herein, and also referred to as “End-Payor Plaintiffs”), both individually and on behalf of a class of end-payor indirect purchasers of Automotive Wire Harness Systems (“Settlement Class”), as more particularly defined in Paragraph 12 below.
Sample 1

Examples of AUTOMOTIVE PARTS ANTITRUST LITIGATION in a sentence

  • Denso International America, Inc., et al., Case No. 2:12-cv-12526- MOB-MKM (E.D. Mich.) IN RE: AUTOMOTIVE PARTS ANTITRUST LITIGATION : : 12-md-02311 : PRODUCT(S): AUTOMOTIVE WIRE HARNESSES : Xxx.


More Definitions of AUTOMOTIVE PARTS ANTITRUST LITIGATION

AUTOMOTIVE PARTS ANTITRUST LITIGATION. Master File No. 2:12-md-02311 Judge Xxxxxxxx X. Xxxxxxx Magistrate Judge Xxxx X. Xxxxxxx Case No. 2:12-cv-00503 Case No. 2:13-cv-01903 IN RE BEARINGS IN RE ELECTRONIC POWERED STEERING ASSEMBLIES THIS DOCUMENT RELATES TO: END-PAYOR ACTIONS This Settlement Agreement (“Agreement”) is made and entered into this 21st day of July, 2016 (“Execution Date”) by and between NSK Ltd., NSK Americas, Inc., NSK Steering Systems Co., Ltd. and NSK Steering Systems America, Inc. (together, “NSK”) and End-Payor Plaintiff Class Representatives (“End-Payor Plaintiffs”), both individually and on behalf of classes of end-payor indirect purchasers of BEARINGS and ELECTRONIC POWERED STEERING ASSEMBLIES (“Settlement Classes”), as more particularly defined in Paragraph 13 below.
Sample 1
AUTOMOTIVE PARTS ANTITRUST LITIGATION. Master File No. 2:12-md-02311 Xxxxxxxxx Xxxxxxxx X. Battani Case No. 2:13-cv-02703 IN RE AIR CONDITIONING SYSTEMS THIS DOCUMENT RELATES TO: END-PAYOR ACTION This Settlement Agreement (“Agreement”) is made and entered into this 11th day of March 2019 (“Execution Date”) by and between Panasonic Corporation (“Panasonic Corp.”) and End-Payor Plaintiff Class Representatives (“End-Payor Plaintiffs”), both individually and on behalf of a class of indirect purchasers of Air Conditioning Systems (“Settlement Class”), as more particularly defined in Paragraph 12 below.
Sample 1
AUTOMOTIVE PARTS ANTITRUST LITIGATION. 2:12-md-02311 Xxxxxxxxx Xxxxxxxx X. Battani Case No. 2:13-cv-02203 Case No. 2:13-cv-02503 FUEL INJECTION SYSTEMS VALVE TIMING CONTROL DEVICES THIS DOCUMENT RELATES TO: END-PAYOR ACTION This Settlement Agreement (“Agreement”) is made and entered into this 18th day of June 2019 (“Execution Date”) by and between Mikuni Corporation (“Mikuni”) and End-Payor Plaintiff Class Representatives (“End-Payor Plaintiffs”), both individually and on behalf of classes of indirect purchasers of Fuel Injection Systems and Valve Timing Control Devices (“Settlement Classes”), as more particularly defined in Paragraph 12 below.
Sample 1
AUTOMOTIVE PARTS ANTITRUST LITIGATION. 2:12-md-02311 Xxxxxxxxx Xxxxxxxx X. Battani Case No. 2:13-cv-02703-MOB-MKM IN RE AIR CONDITIONING SYSTEMS THIS DOCUMENT RELATES TO: END-PAYOR ACTION This Settlement Agreement (“Agreement”) is made and entered into this 11 day of December 2017 (“Execution Date”) by and between XXXXX Behr GmbH & Co. KG and XXXXX Xxxx USA Inc. (together, “XXXXX Behr”), and End-Payor Plaintiff Class Representatives (“End-Payor Plaintiffs”), both individually and on behalf of a class of indirect purchasers of Air Conditioning Systems (“Settlement Class”), as more particularly defined in Paragraph 12 below.
Sample 1

Related to AUTOMOTIVE PARTS ANTITRUST LITIGATION

  • Conventional filtration treatment means a series of processes including coagulation, flocculation, sedimentation, and filtration resulting in substantial particulate removal.

  • Regulatory Approval Application means any application submitted to an appropriate Regulatory Authority seeking any Regulatory Approval.

  • Public Procurement Regulatory Authority (PPRA) means the Government Agency responsible for oversight of public procurement.

  • Third Party Applications means online, Web-based applications and offline software products that are provided by third parties and are identified as third-party applications, including but not limited to those listed on the AppExchange and the Reseller Application.

  • Investigational Product means the Study Drug identified above and the control material, as further detailed in the Protocol;

  • Marketing Approval Application or “MAA” means a New Drug Application (or its equivalent), as defined in the U.S. Food, Drug and Cosmetic Act and the regulations promulgated thereunder, or any corresponding or similar application, registration or certification in any country.

  • Collaborative drug therapy management means participation by an authorized pharmacist and a physician in the management of drug therapy pursuant to a written community practice protocol or a written hospital practice protocol.

  • Autism spectrum disorders means any of the pervasive developmental disorders as defined by the Diagnostic and Statistical Manual of Mental Disorders, 4th edition, published by the American Psychiatric Association, including autistic disorder, Asperger's disorder and pervasive developmental disorder not otherwise specified.

  • Autism spectrum disorder means a neuro-developmental condition typically appearing in the first three years of life that significantly affects a person's ability to communicate, understand relationships and relate to others, and is frequently associated with unusual or stereotypical rituals or behaviours.

  • Biologics License Application or “BLA” means an application requesting permission from the FDA to introduce, or deliver for introduction, a biological product into interstate commerce, or any similar application or submission for marketing authorization of a product filed with a Regulatory Authority to obtain Regulatory Approval for such product in a country or group of countries.

  • Collaborative pharmacy practice agreement means a written and signed

  • Patent Cooperation Treaty means the Patent Cooperation Treaty done at Washington on June 19, 1970;

  • Cannabis production establishment agent registration card means a registration card that the department issues that:

  • Regulatory Action means an administrative, regulatory, or judicial enforcement action, proceeding, investigation or inspection, FDA Form 483 notice of inspectional observation, warning letter, untitled letter, other notice of violation letter, recall, seizure, Section 305 notice or other similar written communication, injunction or consent decree, issued by the FDA or a federal or state court.

  • Clinical nurse specialist means a registered nurse with relevant post-basic qualifications and 12 months’ experience working in the clinical area of his/her specified post-basic qualification, or a minimum of four years’ post-basic registration experience, including three years’ experience in the relevant specialist field and who satisfies the local criteria.

  • DMF means a drug master file, as provided for in 21 CFR § 314.420 or similar submission to or file maintained with the FDA or other Governmental Authority or Regulatory Authority that may be used to provide confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of one or more human drugs.

  • Unassigned medication for respiratory distress means albuterol, levalbuterol, or another medication designated by the executive commission of the Health and Human Services Commission for treatment of respiratory distress, prescribed by an authorized health-care provider in the name of the district with a non-patient-specific standing delegation order for the administration of a medication for respiratory distress, and issued by an authorized health-care provider.

  • Product Complaint means any written, verbal or electronic expression of dissatisfaction regarding the Product, including without limitation reports of actual or suspected product tampering, contamination, mislabeling or inclusion of improper ingredients.

  • Planning Application means the application for [outline/full] planning permission dated [ ] bearing the Council’s reference number [ ];

  • Marketing Authorization Application or “MAA” means an application to the appropriate Regulatory Authority for approval to sell the Product (but excluding Pricing Approval) in any particular country or regulatory jurisdiction.

  • Approval Application means a BLA, NDA or similar application or submission for a Product filed with a Regulatory Authority in a country or group of countries to obtain marketing approval for a biological or pharmaceutical product in that country or group of countries.

  • Drug Approval Application means an application for Regulatory Approval required before commercial sale or use of a Product as a drug in a regulatory jurisdiction.

  • Necessary preconstruction approvals or permits means those permits or approvals required under federal air quality control laws and regulations and those air quality control laws and regulations which are part of the applicable State Implementation Plan.

  • Manufacturing Know-How means all information, techniques, inventions, discoveries, improvements, practices, methods, knowledge, skill, experience and other technology, whether or not patentable or copyrightable, and any copyrights based thereon, relating to or necessary or useful for the production, purification, packaging, storage and transportation of Collaboration Products, including without limitation specifications, acceptance criteria, manufacturing batch records, standard operating procedures, engineering plans, installation, operation and process qualification protocols for equipment, validation records, master files submitted to the FDA, process validation reports, environmental monitoring processes, test data including pharmacological, toxicological and clinical test data, cost data and employee training materials.

  • Pendency of the procurement process means the time period commencing with the public notice of the request for proposals and ending with the award of the contract or the cancellation of the request for proposals.

  • FDA means the United States Food and Drug Administration and any successor agency thereto.